Search
AstraZeneca: Ultomiris® Approved in China for NMOSD Treatment in Adult Patients
2 day ago /
Read about 0 minute
Author：小编
Eculizumab Injection, marketed under the brand name Ultomiris®, has received approval in China for the treatment of adult patients diagnosed with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare and severely disabling autoimmune condition that primarily targets the spinal cord and optic nerves, causing significant impairment to the central nervous system. The approval of Ultomiris® hinges on the promising outcomes of the Phase III CHAMPION-NMOSD clinical trial, offering patients a renewed hope for achieving relapse-free remission.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
